LP
BBIO icon

LMR Partners’s BridgeBio Pharma BBIO Stock Holding History

LMR Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-107,700
Closed -$8.24M – 1468
2025
Q4 		$8.24M Hold
107,700
– – 0.02% 441
2025
Q3 		$5.59M Hold
107,700
– – 0.02% 481
2025
Q2 		$4.65M Hold
107,700
– – 0.03% 460
2025
Q1 		$3.72M Buy
+107,700
New +$3.63M 0.03% 504
2024
Q3 		– Sell
-87,100
Closed -$2.21M – 1299
2024
Q2 		$2.21M Buy
87,100
+47,100
+118% +$1.29M 0.02% 526
2024
Q1 		$1.24M Sell
40,000
-40,000
-50% -$1.36M 0.01% 632
2023
Q4 		$3.23M Buy
+80,000
New +$2.4M 0.04% 400
2023
Q3 		– Sell
-1,055,200
Closed -$18.1M – 942
2023
Q2 		$18.1M Buy
+1,055,200
New +$15.9M 0.2% 111

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LMR Partners's BBIO Position: Q2 2026 in Review

LMR Partners opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 54,130 shares worth $4.03M. The stake represents 0.02% of the portfolio and ranks #722 among its holdings. This is a return to the name: LMR Partners previously reported a position in BBIO as recently as Q3 2025.

LMR Partners first reported a position in BBIO in Q2 2023 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • LMR Partners held 54,130 shares of BridgeBio Pharma worth $4.03M as of Q2 2026.
  • BridgeBio Pharma was a new LMR Partners position in Q2 2026.
  • BridgeBio Pharma made up 0.02% of LMR Partners's portfolio in Q2 2026, its #722 holding.
  • LMR Partners first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 7 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.